Today’s insulin formulations save lives, but achieving tight control over blood-glucose levels remains a daily challenge for those living with type 1 diabetes (T1D). The JDRF Glucose Control Program is committed to making the management of T1D much better and safer through groundbreaking research and clinical trials that aim to develop new ways to help people keep their blood-sugar levels within a healthy range.
Insulin therapy must be calculated carefully, based on food intake, exercise, stress, illness and other (often unpredictable) factors. As a result, people with T1D spend an average of 10 hours a day with blood-sugar levels outside the recommended range, putting them at risk for dangerous high- and low-blood-sugar episodes.
Create next-generation insulins
that will automatically respond to blood-sugar levels
Discover combination therapies
—using insulin and other drugs—to dramatically improve daily blood-sugar management
Prevent dangerous lows
so that no one needs to worry about the risks of low blood-sugar again
“I participated in a clinical trial for an SGLT-2 inhibitor that is typically used for the treatment of type 2 diabetes. The biggest benefit was the fact that I never experienced the high blood sugar sluggishness that comes after every time I eat carbs. It showed me that the small advancements really do make a big difference in the way I live with T1D.”
25 years old, diagnosed at age 20
Many Paths, One Purpose
Our research into glucose control technologies is just one potential pathway to finding a cure for T1D. Explore JDRF’s ambitious research portfolio.
In the last decade, more than $45 million has been invested by JDRF in glucose control research. One day, thanks to improved insulin formulations and other drugs, staying within ideal blood-sugar range is no longer a challenge.